On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
WednesdayJun 14, 2017 2:11 pm

NetworkNewsBreaks – Sorrento Therapeutics, Inc.’s (NASDAQ: SRNE) Pain Subsidiary Reports Positive Data from Adhesion Study of ZTlido™; Shares Higher

Shares of Sorrento Therapeutics (NASDAQ: SRNE) are up 7% mid-day after the company’s pain subsidiary, SCILEX Pharmaceuticals, released positive data regarding its lead investigational product, ZTlido™. During a recently completed comparative adhesion performance study to support the market authorization application (MAA) in the EU, ZTlido™ demonstrated superior adhesion versus the EU reference product, Versatis®. SCILEX said it plans to resubmit the New Drug Application for ZTlido™ to the FDA and the MAA to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom in the second half of 2017. "We are pleased to report our noteworthy data. We believe…

Continue Reading

WednesdayJun 14, 2017 11:32 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) Announces Launch of New Service Module Targeting Hip and Knee Surgical Procedures

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) today announced the planned launch of its new service module for hip and knee surgical procedures, which is scheduled to take place in July 2017. “The launch of this new module follows the successful launch of our spine module, which for the past eight months has been in continuous use in two nationally recognized hospitals, achieving overwhelming success,” Colt Melby, CEO of ORHub, stated in the news release. “Our hips and knees module is the second of many on our technical road map that will allow us to exponentially grow our addressable…

Continue Reading

WednesdayJun 14, 2017 10:59 am

NetworkNewsBreaks – China’s Expansive O2O Commerce Market Suggests Bright Future for Moxian, Inc. (NASDAQ: MOXC)

Online-to-offline (O2O) commerce conducted through click-and-collect has become a hot trend in the United States. In China, O2O goes much further, encompassing various services (such as booking a barber to perform a haircut in your home) that may not be a cost-effective option in Western markets. O2O is blooming in the U.S. and Europe, and its growth prospects are even greater in China, which is why O2O innovator Moxian, Inc. (NASDAQ: MOXC) stands before mounting potential, being based in mainland China and offering a valuable online platform to help Chinese SMEs with brick-and-mortar stores increase their marketing reach through cloud-based…

Continue Reading

WednesdayJun 14, 2017 10:55 am

NetworkNewsBreaks – Research Report Highlights Hefty Market Potential for ChineseInvestors.com, Inc. (CIIX)

ChineseInvestors.com, Inc. (OTCQB: CIIX), which recently took part in SeeThruEquity’s 6th Annual Microcap Investor Conference in early June, offers educational consulting services for Chinese investors and is also pursuing opportunities in the cannabis market.  SeeThruEquity recently increased the price target on CIIX to $3.75 from $2.05, and predicted that revenues from the company’s hemp business could reach 8-digit sales by 2020. “The goal of the company is to be a leading publicly-traded company within the nutritional industry. In addition to its online store based in the free trade zone of Shanghai, China, CIIX is building its first retail store in…

Continue Reading

WednesdayJun 14, 2017 9:25 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Targets Canadian Cannabis Market by Incorporating CBD Biotechnology Inc. in British Columbia

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that it has incorporated CBD Biotechnology Inc. in British Columbia, Canada. “I am delighted about the incorporation of CBD Biotechnology Inc.,” Warren Wang, founder and CEO of CIIX, stated in the news release. “The incorporation of CBD Biotechnology Inc. is a promising step forward towards CIIX's goals to enter the medical marijuana industry. Through its expansion into Canada, CIIX aims generate significant revenues through sales of CBD-based health products, while helping the nearly one million Chinese in Canada to improve their overall health.” Canada promises to play a major role…

Continue Reading

TuesdayJun 13, 2017 12:29 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 13, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: CYTR 10.71% – News: Reforms clinical and regulatory executive team CTRV 6.73% – News: Presenting at the 2017 BIO International Convention on June 21 SRNE 6.56% – News: Contributes to the formation of Celularity, Inc. AMMA 6.42% – News: Law firm issues reminder of June 16 lead plaintiff deadline QTRH 5.54% – News: Enters patent license agreement with Amazon.com OVAS 4.69% – News: Completes enrollment in ongoing OvaPrime clinical study MNGA 4.19% – News:…

Continue Reading

TuesdayJun 13, 2017 12:29 pm

NetworkNewsBreaks – NeuroMetrix, Inc. (NASDAQ: NURO) Shares Tick Higher on News of U.S. Patent for Quell Wearable Pain Relief Technology

NeuroMetrix (NASDAQ: NURO) shares are up 4% on news that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,675,801 covering claims for technology regarding Quell®, the company’s wearable pain relief device. The novel mechanisms that enable Quell® users to safely achieve pain relief therapy over extended periods of time are covered in the newly issued patent. Such claims include the technology to monitor the amount of time that Quell is worn both continually and in total, as well as technology that delivers notifications to the user to maximize safety. "Quell is unique in the fact that the…

Continue Reading

TuesdayJun 13, 2017 10:04 am

NetworkNewsBreaks – Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) Reports Confirmed PATSCAN CMR™ Sales Commitments of $2.7M

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF), developer of the award-winning PATSCAN CMR™ concealed weapons detection system, this morning announced that it has recorded $2.7 million in confirmed sales commitment since commencing product marketing just three months ago ahead of the ISC West trade show in Las Vegas. “Our roll-out program initially conceived finalizing our engineering in early spring in order to meet Industry Canada and FCC certification requirements by late summer,” Dinesh Kandanchatha, president and CTO of Patriot One, stated in the news release. “We have informed our supply chain partners of the accelerating demand, and I am…

Continue Reading

TuesdayJun 13, 2017 9:32 am

NetworkNewsBreaks – Converde Energy USA, Inc. (XFUL) Enters Securities Purchase Agreement with GPL Ventures LLC; Retains Minivest as Advisor

Converde Energy USA, Inc. (OTC: XFUL) this morning announced its entry into a securities purchase agreement with GPL Ventures LLC (“GPL”) through which GPL will have the option to purchase up to $3 million in XFUL common stock when the company has qualified the necessary number of shares under Regulation A through an offering statement. Per the update, XFUL intends to file the offering statement within the next 30 days. “We are very excited to have this investment agreement in place as a primary funding vehicle for the company,” Brad Domitrovitsch, chairman and CEO of XFUL, stated in the news…

Continue Reading

TuesdayJun 13, 2017 9:00 am

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Teams with Pharmaseed to Advance Development of INM-750

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into an agreement with Pharmaseed Ltd., Israel’s largest GLP-certified pre-clinical contract research organization. Under the terms of this agreement, the Pharmaseed development team will now play a key role in the ongoing development of InMed’s lead compound, INM-750, which is a proprietary, topical cannabinoid product candidate that’s currently being studied as a therapy in epidermolysis bullosa and other potential dermatological and wound-healing applications. “This agreement with Pharmaseed now adds one of Israel's leading formulation development teams to our efforts and represents an important strategic…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217